دورية أكاديمية
Endovascular treatment of cerebral sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia.
| العنوان: | Endovascular treatment of cerebral sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia. |
|---|---|
| المؤلفون: | Weller J; Department of Neurology, University Hospital Bonn, Bonn, Germany., Krzywicka K; Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., van de Munckhof A; Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Dorn F; Department of Neuroradiology, University Hospital Bonn, Bonn, Germany., Althaus K; Department of Neurology, Ulm University Hospital, Ulm, Germany., Bode FJ; Department of Neurology, University Hospital Bonn, Bonn, Germany., Bandettini di Poggio M; Department of Neuroscience, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Buck B; Division of Neurology, University of Alberta Hospital, Edmonton, AB, Canada., Kleinig T; Department of Neurology, Royal Adelaide Hospital, Adelaide, SA, Australia., Cordonnier C; Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France., Dizonno V; Vancouver Stroke Program, Division of Neurology, University of British Columbia, Vancouver, BC, Canada., Duan J; Department of Neurology and Emergency, Xuanwu Hospital, Capital Medical University, Beijing, China., Elkady A; Department of Neurology, Saudi German Hospital, Jeddah, Saudi Arabia., Chew BLA; Department of Neurology, John Hunter Hospital, Newcastle, NSW, Australia., Garcia-Esperon C; Department of Neurology, John Hunter Hospital, Newcastle, NSW, Australia., Field TS; Vancouver Stroke Program, Division of Neurology, University of British Columbia, Vancouver, BC, Canada., Legault C; Division of Neurology, McGill University Health Centre, Montreal, QC, Canada., Morin Martin M; Department of Neurology, Hospital Complex of Toledo, Toledo, Spain., Michalski D; Department of Neurology, University of Leipzig, Leipzig, Germany., Pelz J; Department of Neurology, University of Leipzig, Leipzig, Germany., Schoenenberger S; Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany., Nagel S; Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.; Department of Neurology, Klinikum Ludwigshafen, Ludwigshafen, Germany., Petruzzellis M; Neuroradiology Unit, Azienda Ospedaliera Consorziale Policlinico di Bari, Italy., Raposo N; Department of Neurology, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France and Inserm, Toulouse NeuroImaging Center, Université de Toulouse, Toulouse, France., Skjelland M; Department of Neurology, Oslo University Hospital, Oslo, Norway., Zimatore DS; Neuroradiology Unit, Azienda Ospedaliera Consorziale Policlinico di Bari, Italy., Aaron S; Neurology Unit, Department of Neurological Sciences, Christian Medical College and Hospital, Vellore, Tamil Nadu, India., Sanchez van Kammen M; Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Aguiar de Sousa D; CEEM and Institute of Anatomy, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.; Stroke Centre, Lisbon Central University Hospital, Lisbon, Portugal., Lindgren E; Department of Neurology, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden., Jood K; Department of Neurology, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden., Scutelnic A; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Heldner MR; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Poli S; Department of Neurology & Stroke, Eberhard-Karls University, Tuebingen, Germany and Hertie Institute for Clinical Brain Research, Eberhard-Karls University, Tuebingen, Germany., Arauz A; Instituto Nacional de Neurologia y Neurocirugia, Mexico City, Mexico., Conforto AB; Hospital das Clinicas/São Paulo University and Hospital Israelita Albert Einstein, São Paulo, Brazil., Putaala J; Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Tatlisumak T; Department of Neurology, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.; Department of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Arnold M; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Coutinho JM; Department of Neurology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Günther A; Department of Neurology, Jena University Hospital, Jena, Germany., Zimmermann J; Department of Neurology, University Hospital Bonn, Bonn, Germany., Ferro JM; Centro de Estudas Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Portugal. |
| المصدر: | European stroke journal [Eur Stroke J] 2024 Mar; Vol. 9 (1), pp. 105-113. Date of Electronic Publication: 2023 Sep 28. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: SAGE Publications Ltd Country of Publication: England NLM ID: 101688446 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2396-9881 (Electronic) Linking ISSN: 23969873 NLM ISO Abbreviation: Eur Stroke J Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : SAGE Publications Ltd, [2016]- |
| مواضيع طبية MeSH: | Purpura, Thrombocytopenic, Idiopathic* , Thrombocytopenia*/chemically induced , Vaccines* , Sinus Thrombosis, Intracranial*/etiology, Humans ; COVID-19 Vaccines/adverse effects |
| مستخلص: | Introduction: There is little data on the role of endovascular treatment (EVT) of cerebral venous sinus thrombosis (CVST) due to vaccine-induced immune thrombotic thrombocytopenia (VITT). Here, we describe clinical characteristics and outcomes of CVST-VITT patients who were treated with EVT. Patients and Methods: We report data from an international registry of patients who developed CVST within 28 days of SARS-CoV-2 vaccination, reported between 29 March 2021 and 6 March 2023. VITT was defined according to the Pavord criteria. Results: EVT was performed in 18/136 (13%) patients with CVST-VITT (92% aspiration and/or stent retrieval, 8% local thrombolysis). Most common indications were extensive thrombosis and clinical or radiological deterioration. Compared to non-EVT patients, those receiving EVT had a higher median thrombus load (4.5 vs 3). Following EVT, local blood flow was improved in 83% (10/12, 95% confidence interval [CI] 54-96). One (6%) asymptomatic sinus perforation occurred. Eight (44%) patients treated with EVT also underwent decompressive surgery. Mortality was 50% (9/18, 95% CI 29-71) and 88% (8/9, 95% CI 25-66) of surviving EVT patients achieved functional independence with a modified Rankin Scale score of 0-2 at follow-up. In multivariable analysis, EVT was not associated with increased mortality (adjusted odds ratio, 0.66, 95% CI 0.16-2.58). Discussion and Conclusion: We describe the largest cohort of CVST-VITT patients receiving EVT. Half of the patients receiving EVT died during hospital admission, but most survivors achieved functional independence. Competing Interests: Declaration of conflicting interestThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AA serves as an advisory board member for Bayer and Bristol Myers Squibb and consulting fees for Boheringer Ingelheim. ABC received consulting fees from Boehringer Ingelheim. SM reports grants from Bayer, Pfizer, Boehringer Ingelheim and Daiichi Sankyo paid to her institution, and personal fees from Bayer, BMS/Pfizer, Boehringer Ingelheim, Abbvie, Portola/Alexion and Daiichi Sankyo paid to her institution. AG received speaker’s honoraria from Boehringer Ingelheim, Daichii Sankyo, Pfizer, Occlutech, Merz, and Ipsen. CGE received funding to attend a conference from Boehringer Ingelheim and Bayer and speaker honoraria from the AAN. AS has received a grant from Swiss Heart Foundation. CC received speaker honoraria from Boehringer Ingelheim, personal fees for advisory board participation from AstraZeneca and Biogen, and personal fees from Biogen and Bristol Myers Squibb. CGE received travel funding from Boehringer Ingelheim and Bayer and speaker honoraria from the AAN. DAS reports travel support from Boehringer Ingelheim, DSMB participation for the SECRET trial, advisory board participation for AstraZeneca and membership on the ESO Executive Committee. EL received grants from the Swedish State, Swedish Neurologic Society, Elsa and Gustav Lindh’s Foundation, P-O Ahl’s Foundation and Rune and Ulla Amlöv’s Foundation. FD is a consultant/proctor for Cerenovus/Johnson&Johnson, Balt, Cerus Endovascular and Phenox and received speaker’s honoraria from Acandis, Stryker, Cerenovus/Johnson&Johnson, Asahi and research support from Cerenovus/Johnson&Johnson. JMC received grants paid to his institution from Boehringer Ingelheim and Bayer for DSMB participation by Bayer. JMF reports fees and DSMB or Advisory Board participation for Boehringer Ingelheim and consulting fees from Bayer. JPa received personal fees from Boehringer Ingelheim, Bayer, Herantis Pharma and Abbott and stock ownership in Vital Signum. MA reports compensation from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Covidien, Daiichi Sankyo, Novartis, Sanofi, Pfizer, Medtronic and research grants from the Swiss National Science Foundation and the Swiss Heart Foundation. MP received personal fees for advisory board participation from Alexion. MRH reports grants from the Swiss Heart Foundation, the Bangerter Foundation, Swiss National Science Foundation, and SITEM Research Funds, and Advisory Board participation for Amgen. NR received research grants from Fulbright, Harvard University and Philippe Foundation. RL reports fees paid to his institution by Boehringer Ingelheim, Genentech, Ischemaview, Medtronic, and Medpass. SN has received consulting fees from Brainomix and lecture fees from Boehringer Ingelheim and BMS-Pfizer. SP received research support from BMS/Pfizer, Boehringer-Ingelheim, Daiichi Sankyo, European Union, German Federal Joint Committee Innovation Fund, and German Federal Ministry of Education and Research, Helena Laboratories and Werfen and speakers’ honoraria/consulting fees from Alexion, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS/Pfizer, Daiichi Sankyo, Portola, and Werfen. TK received personal fees from Boehringer Ingelheim. TSF received study medication from Bayer Canada and personal fees from HLS Therapeutics. TT has received personal fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Inventiva, and Portola Pharma. All other authors declare that there is no conflict of interest. |
| References: | Stroke. 2021 Jul;52(7):2478-2482. (PMID: 33914590) J Neurointerv Surg. 2022 Sep;14(9):853-857. (PMID: 34782400) Eur J Neurol. 2017 Oct;24(10):1203-1213. (PMID: 28833980) JAMA Neurol. 2020 Aug 1;77(8):966-973. (PMID: 32421159) Neurol Sci. 2022 Mar;43(3):1499-1502. (PMID: 35001190) N Engl J Med. 2021 Jun 3;384(22):2092-2101. (PMID: 33835769) Stroke. 2015 May;46(5):1263-8. (PMID: 25899238) AJNR Am J Neuroradiol. 2022 Jan;43(1):98-101. (PMID: 34949591) J Neurointerv Surg. 2022 Aug;14(8):788-793. (PMID: 35022302) Lancet. 2016 Apr 23;387(10029):1723-31. (PMID: 26898852) Eur J Neurol. 2023 May;30(5):1335-1345. (PMID: 36773014) Stroke. 2011 Apr;42(4):1158-92. (PMID: 21293023) Stroke. 2022 Oct;53(10):3206-3210. (PMID: 36082668) N Engl J Med. 2021 Oct 28;385(18):1680-1689. (PMID: 34379914) JAMA Neurol. 2021 Nov 1;78(11):1314-1323. (PMID: 34581763) Lancet. 2021 Sep 25;398(10306):1147-1156. (PMID: 34370972) Stroke. 2020 Apr;51(4):1174-1181. (PMID: 32114929) J Neurointerv Surg. 2022 Sep;14(9):849-850. (PMID: 35177518) Front Neurol. 2021 Jul 30;12:721146. (PMID: 34393988) Stroke. 2004 Mar;35(3):664-70. (PMID: 14976332) Ann Neurol. 2022 Oct;92(4):562-573. (PMID: 35689346) |
| فهرسة مساهمة: | Keywords: COVID-19; Intracranial thrombosis; thrombectomy; thrombocytopenia; vaccination; venous thrombosis |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) 0 (Vaccines) |
| تواريخ الأحداث: | Date Created: 20230929 Date Completed: 20240306 Latest Revision: 20240308 |
| رمز التحديث: | 20240308 |
| مُعرف محوري في PubMed: | PMC10916823 |
| DOI: | 10.1177/23969873231202363 |
| PMID: | 37771138 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2396-9881 |
|---|---|
| DOI: | 10.1177/23969873231202363 |